Goods & Services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Therapeutic companion diagnostics in the form of reagents for assisting with predicting the effects of medication, the existence or non-existence of side effects and with selecting medication to be administered relating to the respective patient; In vitro diagnostic preparations, in particular Reagents, solutions and test strips for analysing biological samples for clinical use and for medical and diagnostic purposes; Reagents, Solutions and Test strips For medical and clinical use; Diagnostic reagents for medical use, for analysing body fluids, in particular saliva and blood; Test strips for detecting substances in body fluids, in particular saliva and blood, for laboratory use and for medical use; Compounds, in particular Active substances and/or reagents, materials and preparations for clinical diagnostics or therapeutic companion diagnostics; Chemical preparations for use in medical diagnostics, in particular preparations for personalised medicine and/or gene analysis and/or genome sequencing; Chemical preparations for use in RNA, DNA and antibody analysis, in particular in the field of personalised medicine; Ready-to-use injections filled with pharmaceutical preparations; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for activating cell function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceuticals and Pharmaceutical preparations, The aforesaid goods for the prevention and treatment of gastrointestinal diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Medicinal products, in particular Medical devices for conducting in-vitro diagnostic test procedures; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Pre-filled syringes for medical purposes; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines; Diagnostic apparatus for medical purposes; Medical apparatus and instruments for extracting body fluids, in particular saliva and blood samples; Medical diagnostic apparatus and instruments for analysing body fluids, in particular saliva and blood; Medical apparatus and instruments, and components and fittings therefor, for analysing DNA, RNA and antibodies; Clinical and medical laboratory test apparatus for diagnostic use in the following fields: Disease diagnostics, in particular Personalised medicine and companion diagnostics. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Services in the the following fields: Organisational development, personnel development services, self improvement, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals; Medical analysis, in particular Test procedures in the following fields: Personalised medicine and companion diagnostics; Conducting of RNA, DNA and antibody analysis, in particular in the following fields: Personalised medicine and companion diagnostics; Development and research in the medical fields of gastroenterology and hepatology. Medical services, in particular Treatment methods in the following fields: Personalised medicine and companion diagnostics; Diagnostic services, in particular Companion diagnostics for assessing the effectiveness and/or safety of medicines; Medical and diagnostic services in the medical fields of gastroenterology and hepatology.

Goods & Services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Therapeutic companion diagnostics in the form of reagents for assisting with predicting the effects of medication, the existence or non-existence of side effects and with selecting medication to be administered relating to the respective patient; In vitro diagnostic preparations, in particular Reagents, solutions and test strips for analysing biological samples for clinical use and for medical and diagnostic purposes; Reagents, Solutions and Test strips For medical and clinical use; Diagnostic reagents for medical use, for analysing body fluids, in particular saliva and blood; Test strips for detecting substances in body fluids, in particular saliva and blood, for laboratory use and for medical use; Compounds, in particular Active substances and/or reagents, materials and preparations for clinical diagnostics or therapeutic companion diagnostics; Chemical preparations for use in medical diagnostics, in particular preparations for personalised medicine and/or gene analysis and/or genome sequencing; Chemical preparations for use in RNA, DNA and antibody analysis, in particular in the field of personalised medicine; Ready-to-use injections filled with pharmaceutical preparations; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for activating cell function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceuticals and Pharmaceutical preparations, The aforesaid goods for the prevention and treatment of gastrointestinal diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Medicinal products, in particular Medical devices for conducting in-vitro diagnostic test procedures; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Pre-filled syringes for medical purposes; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines; Diagnostic apparatus for medical purposes; Medical apparatus and instruments for extracting body fluids, in particular saliva and blood samples; Medical diagnostic apparatus and instruments for analysing body fluids, in particular saliva and blood; Medical apparatus and instruments, and components and fittings therefor, for analysing DNA, RNA and antibodies; Clinical and medical laboratory test apparatus for diagnostic use in the following fields: Disease diagnostics, in particular Personalised medicine and companion diagnostics. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Services in the the following fields: Organisational development, personnel development services, self improvement, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals; Medical analysis, in particular Test procedures in the following fields: Personalised medicine and companion diagnostics; Conducting of RNA, DNA and antibody analysis, in particular in the following fields: Personalised medicine and companion diagnostics; Development and research in the medical fields of gastroenterology and hepatology. Medical services, in particular Treatment methods in the following fields: Personalised medicine and companion diagnostics; Diagnostic services, in particular Companion diagnostics for assessing the effectiveness and/or safety of medicines; Medical and diagnostic services in the medical fields of gastroenterology and hepatology.

Abstract

Disclosed is an orally applicable suspension comprising a) topically acting micronized budesonide, b) an aqueous base, c) at least one viscosity-increasing agent selected from a methylcellulose or a derivative thereof, d) a buffering agent which allows the adjustment of the final suspension to a pH value of 3.5 to 4.5, e) an antimicrobial preservative, f) a suspension stabilizing agent, in particular ethylenediaminetetramethyl acetic acid, whereby the suspension has a dynamic viscosity in the range of 800 mPa*s to 2000 mPa*s and the final suspension contains a concentration of 0.1 mg/ml to 0.5 mg/ml budesonide for use in the treatment of eosinophilic esophagitis of a patient having an age of about 1 year to about 17 years whereby 0.5 to 1.0 mg budesonide are administered in 2.5 to 5.0 ml suspension once or twice a day.

IPC Classes  ?

• A61K 9/10 - DispersionsEmulsions
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/38 - CelluloseDerivatives thereof
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Goods & Services

Medicinal preparations and substances; Pharmaceuticals and natural remedies; Pharmaceutical drugs; Pharmaceutical products and preparations; Diagnostic preparations and materials, for medical and veterinary purposes; Diagnostic agents for pharmaceutical use; Dietary supplements and dietetic preparations; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting metabolism; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of inflammatory and bacterial diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of bacterial disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of immune system disorders and autoimmune disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for immune system adjustment; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for regulating the immune system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of digestive system diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of hypertension; pharmaceutical preparations and agents for activating cellular function; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the peripheral nervous system; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of kidney diseases and disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of liver diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of metabolic disorders and diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of skin disorders and problems; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of bone diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of rheumatic diseases; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of depression; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention and treatment of musculoskeletal diseases; Pharmaceutical products, products for preventing and treating stomach and intestinal disorders; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in organ transplantation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in dermatology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for use in urology; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hypercholesterolemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of hyperlipidemia; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the prevention of osteoporosis; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of the digestive tract, including the oesophagus; Pharmaceutical preparations and Pharmaceuticals, namely Capsules, Powders, Tablets, Sachets, Juices, Suspensions, Granules, enema preparations, Suppositories and Suppositories [for rectal application], rectal foam for pharmaceutical purposes; Chemical preparations for pharmaceutical purposes; Drug delivery agents that facilitate the delivery of pharmaceutical preparations; Drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations, in particular including plant-based preparations, and preparations for the treatment of constipation, coeliac disease, haemorrhoids, pancreatitis [in particular acute pancreatitis], high cholesterol, zinc deficiency, irritable bowel syndrome or supportive therapies for diarrhoea; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for intestinal cleansing before a colonoscopy; Immunosuppressants and cortisol preparations for the treatment of organ transplants, inflammatory bowel disease, skin diseases and rheumatic joint inflammation; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for supporting the body in connection with an organ transplant; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of rheumatoid arthritis, chronic inflammatory bowel disease, in particular Crohn's disease or ulcerative colitis, systemic lupus erythematosus, dermatomyositis, polymyositis, chronic active autoimmune hepatitis, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the treatment of chronic intestinal inflammation, in particular microscopic colitis, chronic inflammation of the liver [autoimmune hepatitis] and inflammatory diseases of the oesophagus [eosinophilic oesophagitis]; Pharmaceutical preparations and Pharmaceuticals, The aforesaid goods for the dissolving of gallstones, for the treatment of chronic diseases of the biliary tract and for the treatment of liver diseases, in particular cirrhosis of the liver or liver disease in connection with cystic fibrosis [mucoviscidosis]. Medical apparatus and instruments; Pharmaceutical instruments; Injection device for pharmaceuticals; Applicators for pharmaceutical preparations; Apparatus for the administration of medicines and pharmaceutical preparations; Autoinjectors for the administration of pharmaceutical preparations; Medical apparatus for facilitating the inhalation of pharmaceutical preparations; Medical apparatus for introducing pharmaceutical preparations into the human body; Implantable subcutaneous drug delivery devices; Medical instruments for therapeutic drug monitoring; Metering pumps for delivering drugs in measured quantities [medical use]; Applicators for medications; Receptacles for applying medicines. Printed matter; Educational and teaching materials; Printed books, magazines, newspapers, and other paper-based media; All the aforesaid goods solely for use in the field of medical training and further training, in particular in the field of pharmacological training and further training. Advertising, marketing and promotional services; Public relations services; Promotion, advertising and marketing of on-line websites; Online advertisements; Computerised business promotion; Provision of space on web-sites for advertising goods and services; Dissemination of advertising for others via an on-line communications network on the internet; Human resources management and recruitment services; Business assistance, management and administrative services; Business consultancy and advisory services; Charitable activities: Organisational development, personnel development services and Personal development from an professional business perspective, Corporate communications services, Corporate branding; Advertising services to create corporate and brand identity; Distribution of advertising, marketing and promotional material; Product demonstrations and product display services; Services with regard to product presentation to the public; Provision and rental of advertising space, time and media; Trade show and commercial exhibition services; Conducting, arranging and organizing trade shows and trade fairs for commercial and advertising purposes; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Education and instruction services; Providing facilities for educational purposes; Entertainment, education and instruction services; Educational services in the healthcare sector; Organisation of conferences, exhibitions and competitions; Arranging and conducting of training courses, Arranging and conducting of meetings in the field of education; Arranging, conducting and organisation of training courses, arranging, organising and conducting meetings, Arranging, organising and conducting lectures, Arranging, organising and conducting of seminars, arranging, conducting and organizing webinars, Arranging, organisation and conducting of congresses and Arranging, conducting and organisation of symposiums, The aforesaid services in particular in the field of organisational development, personnel development, personality development, corporate communications, corporate branding; Publishing, reporting, and writing of texts; Publishing services (including electronic publishing services); Publishing services; Electronic publishing services; Publishing services; Providing electronic publications; Providing online electronic publications, not downloadable; Providing online videos, not downloadable; Providing on-line non-downloadable audio content; Electronic library services for the supply of electronic information (including archive information) in the form of text, audio and/or video information; Audio, video and multimedia productions; Multimedia publishing of printed matter; All the aforesaid services in the field of health and medicine and not in connection with travel, country information, orientation and/or navigation. Medical and pharmacological research services; Development of pharmaceutical preparations and medicines; Conducting clinical trials for pharmaceutical products; Consultancy relating to pharmaceutical research and development; Research and development for the pharmaceutical industry; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Providing information about the results of clinical trials for pharmaceutical products; Pharmaceutical drug development services; Inspection of pharmaceuticals; Pharmaceutical product evaluation; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Laboratory research services relating to pharmaceuticals.

Abstract

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole

Abstract

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Orodispersible effervescent tablets comprising budesonide are administered to patients suffering from eosinophilic esophagitis whereby a complete mucosal healing (i.e., deep endoscopic AND deep histological remission) and even a deep disease remission (i.e., deep clinical AND deep endoscopic AND deep histological remission) is achieved by a treatment regimen of administering said orodispersible effervescent tablets for at least six weeks to twelve weeks for the induction period and thereafter up to three a years as maintenance treatment.

IPC Classes  ?

• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Goods & Services

Pharmaceutical preparations for the treatment of the intestinal tract including the esophagus

Goods & Services

Pharmaceutical preparations for the treatment of the intestinal tract and the liver

Abstract

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection

Abstract

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations for the treatment of metabolic diseases and diseases of the digestive tract and liver.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H- imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2- dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and/or in the prophylaxis or treatment of a liver disease or liver disorder.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.

IPC Classes  ?

• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2- (2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl- 1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to an oral formulation adapted for selective delivery of a drug to the small intestine of a mammal comprising or consisting of: a plurality of particles in form of coated granules, coated pellets, coated beads, coated minicapsules, or coated minitablets, each particle containing (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2-enoate of formula (I), or an enantiomer, a solvate, a hydrate or a pharmaceutically acceptable salt thereof as the drug, a core material, and an enteric coating polymer, wherein each particle is coated with at least one coating layer containing or consisting of the enteric coating polymer; a preparation method of said oral formulation; and a medical use of said oral formulation in prophylaxis or treatment of intestinal fibrosis, in particular, fibrostenotic Crohn's disease.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/50 - Microcapsules
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).

IPC Classes  ?

• C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The invention describes the provision of an amorphous solid dispersion of RhuDex® choline salt. The oral, gastro-resistant formulation is provided with a specific release characteristic. Release is realized at pH values from 6 to 7 in the region of the upper intestine. This region is specifically advantageous if pharmaceutical formulations aim to reach the liver as the primary target organ.

IPC Classes  ?

• A61K 9/14 - Particulate form, e.g. powders
• A61K 9/50 - Microcapsules
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Orodispersible effervescent tablets comprising budesonide are administered to patients suffering from eosinophilic esophagitis whereby a complete mucosal healing (i.e., deep endoscopic AND deep histological remission) and even a deep disease remission (i.e., deep clinical AND deep endoscopic AND deep histological remission) is achieved by a treatment regimen of administering said orodispersible effervescent tablets for at least six weeks to twelve weeks for the induction period and thereafter up to three years as maintenance treatment.

IPC Classes  ?

• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

A compound of formula (I) or a salt thereof are provided: A compound of formula (I) or a salt thereof are provided: A compound of formula (I) or a salt thereof are provided: wherein R1, X and R3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

IPC Classes  ?

• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07C 211/13 - Amines containing three or more amino groups bound to the carbon skeleton
• C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
• C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
• C07C 223/02 - Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
• C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
• C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
• C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups

Abstract

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat inflammatory bowel disease, or to prevent a relapse. The enema for rectal application containing budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 6 weeks in order to treat inflammatory bowel disease, or to prevent a relapse; the enema for rectal application described above, in which a dose of budesonide is 2.0 mg per dose; the enema for rectal application according to any one of the above, which is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; the enema for rectal application according to any one of the above, which has a foamy shape or a liquid shape.

IPC Classes  ?

• A61K 9/12 - AerosolsFoams
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The present invention relates to a formulation in particular an oral formulation for the prophylaxis and treatment of TG2-related disorders like fibrosis in particular diabetic nephropathy and/or diabetic associated non-alcoholic steatohepatitis (NASH) and/or non-alcoholic steatohepatitis, and its use in the prophylaxis and/or treatment of fibrosis in particular nephropathy, NASH, idiopathic pulmonary fibrosis, and cystic fibrosis. Further, the present application relates also to the use of (S,E)-methyl-7-(1-(2-(2- ethylbutylamino)-2-oxoethyl)-2-oxo-1,2-dihydro-pyridin-3-ylamino)-6-(1-methyl-1H- imidazole-5-carboxamido)-7-oxohept-2-enoate as hepatoprotectant, i.e. as hepatoprotective agent. In addition the present invention relates to a pharmaceutical composition comprising (S,E)-methyl-7-(1-(2-(2-ethylbutylamino)-2-oxoethyl)-2-oxo-1,2- dihydro-pyridin-3-ylamino)-6-(1-methyl-1H-imidazole-5-carboxamido)-7-oxohept-2- enoate for use as hepatoprotective agent and for use in the protection of the liver against liver toxicity, the improvement of liver function, and/or in the prophylaxis or treatment of a liver disease or liver disorder.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 13/10 - Drugs for disorders of the urinary system of the bladder
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present invention relates to a systemic formulation, in particular an oral formulation, for the prophylaxis and/or treatment of coeliac disease, i.e. for use in the prophylaxis and/or treatment of coeliac disease.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases

Goods & Services

(1) Pharmaceutical preparations, namely for the domains of gastroenterology and hepatology.

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of gastrointestinal diseases and disorders, pharmaceutical preparations for the treatment of hepatological diseases and disorders.

Abstract

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmaco-kinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has a very good medicinal safety.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 9/50 - Microcapsules
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes, pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Goods & Services

Pharmaceuticals.

Goods & Services

Pharmaceuticals.

Goods & Services

Pharmaceuticals.

Abstract

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse; has a foamy, more rigid to a more liquid, gel-like structure.

IPC Classes  ?

• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 9/12 - AerosolsFoams
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

IPC Classes  ?

• A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
• A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/20 - Pills, lozenges or tablets

Abstract

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

An optimized pharmaceutical formulation for the treatment of inflammatory diseases of the colon is disclosed, wherein the pharmaceutical formulation is a capsule containing pellets, which capsule is suitable for oral administration and delivers the active substance in a targeted manner to the site of action, namely the colon. This is achieved by a complex and multiple coating of pellets, which permit a modified release of active substance. The release of the active substance is at its maximum only in the colon, with at the same time low blood plasma levels. The results of the pharmaceutical tests concerning in vitro release are corroborated by the results in pharmacokinetic and clinical studies and the clinical efficacy demonstrated by these. The formulation according to the invention has very good medicinal safety.

IPC Classes  ?

• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/50 - Microcapsules
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/20 - Pills, lozenges or tablets

Abstract

A compound of formula (I) or a salt thereof are provided: 3 are defined in the specification, useful in the treatment of disorders mediated by KMO such as acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

IPC Classes  ?

• C07D 263/58 - BenzoxazolesHydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07C 309/30 - Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
• C07C 279/14 - Derivatives of guanidine, i.e. compounds containing the group the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
• C07C 211/13 - Amines containing three or more amino groups bound to the carbon skeleton
• C07C 215/10 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
• C07C 223/02 - Compounds containing amino and —CHO groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms of the carbon skeleton
• C07C 229/26 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
• C07C 211/27 - Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains

Abstract

The present invention relates to methods and/or uses for treating pancreatitis, kidney diseases and other various disorders as described herein, for conditions or disorders mediated by KMO inhibitors, which comprises administering 6-chlorobenzoxazine compounds of Formula (I): pharmaceutically acceptable salts and/or corresponding pharmaceutical compositions thereof.

IPC Classes  ?

• A61K 31/00 - Medicinal preparations containing organic active ingredients
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to the use of Nor-UDCA in the treatment of hepatic steatosis in patients having a hepatic fat fraction of greater than 10%.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Goods & Services

Pharmaceutical preparations.

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases.

Goods & Services

(1) Pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases

Abstract

The present invention relates to an oral enteric high-dose tablet comprising mesalazine as the active substance as well as its use.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups

Abstract

Disclosed is a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically compatible salt or derivative thereof, and at least 80 wt % of a solid fat or a mixture of different solid fats, based on the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

IPC Classes  ?

• A01N 37/00 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
• A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
• A01N 37/12 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group , wherein Cn means a carbon skeleton not containing a ringThio-analogues thereof
• A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
• A61K 31/24 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
• A01N 25/00 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]

Abstract

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

Provided is an enema for rectal application containing budesonide as an active ingredient in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application contains budesonide as the active ingredient, in which 1.5 to 2.5 mg of budesonide per dose is administered twice a day for 12 weeks in order to treat an inflammatory bowel disease, or to prevent a relapse. The enema for rectal application comprises several doses whereby the most preferable dose of budesonide is 2.0 mg per dose. The enema for rectal application is taken in order to treat ulcerative colitis or Crohn's disease, or to prevent a relapse: has a foamy, more rigid to a more liquid, gel-like structure.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/08 - Solutions
• A61K 9/12 - AerosolsFoams
• A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Abstract

Compounds of formula (I) and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel disease, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to a compound of formula (I) or pharmaceutically acceptable salts thereof, which are Kynurenine monooxygenase (KMO) inhibitors, which are useful in the treatment of various disorders, which may include, but are not limited to, for diseases such as, for example: acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compound of formula (I) and salts thereof are KMO inhibitors and may be useful in the treatment of various disorders, for example acute pancreatitis, chronic kidney disease, acute kidney disease, acute kidney injury, other conditions associated with systemic inflammatory response syndrome (SIRS), Huntington's disease, Alzheimer's disease, spinocerebellar ataxias, Parkinson's disease, AIDS-dementia complex, HIV infection, amylotrophic lateral sclerosis (ALS), depression, schizophrenia, sepsis, cardiovascular shock, severe trauma, acute lung injury, acute respiratory distress syndrome, acute cholecystitis, severe burns, pneumonia, extensive surgical procedures, ischemic bowel, severe acute hepatic disease, severe acute hepatic encephalopathy or acute renal failure.

IPC Classes  ?

• A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Goods & Services

(1) Intestinal disorder medicine for the treatment of ulcerative colitis.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations for the treatment of inflammation of the upper gastrointestinal tract

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

The invention relates to an oral gastric-juice resistant high dose tablet comprising mesalazine as an active substance. The invention also relates to the use thereof.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/28 - DrageesCoated pills or tablets
• A61K 31/606 - Salicylic acidDerivatives thereof having amino groups

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Goods & Services

Pharmaceutical preparations.

Abstract

The present invention relates to a pure polymorph of Nor-UDCA or Bis-nor-UDCA, or of a pharmaceutically acceptable salt thereof. The invention further provides a pharmaceutical composition comprising the polymorph of the invention, and a method for preparing the polymorph. The invention includes the pharmaceutical use of the polymorph or of the pharmaceutical composition of the invention.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C07J 7/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms

Abstract

The invention relates to a storage-stable pharmaceutical formulation for rectal administration, containing budesonide or a pharmaceutically-compatible salt or derivative thereof, and at least 80 wt.% of a solid fat or a mixture of different solid fats in relation to the total weight of the formulation, as well as at least one anti-oxidation agent that is compatible therewith.

IPC Classes  ?

• A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Abstract

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. A pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/20 - Pills, lozenges or tablets
• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Goods & Services

Pharmaceutical preparations, other than for prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Goods & Services

Pharmaceutical preparations, namely for treating the digestive tract.

Goods & Services

Pharmaceutical preparations, other than prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Goods & Services

Pharmaceutical preparations, other than prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Abstract

Disclosed is an optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus. Said pharmaceutical formulation in the form of an orodispersible effervescent tablet is stable, easy to produce, and can be used without dissolving same in a liquid. It is not necessary to drink anything with the tablet as this would reduce the time that the budesonide solution remains in the affected regions of the esophagus. The effervescent tablet of the invention surprisingly resulted in an unexpectedly high rate of histological remission in patients with active eosinophilic esophagitis.

IPC Classes  ?

• A61K 9/46 - Pills, lozenges or tablets effervescent
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin

Goods & Services

Pharmaceutical preparations, other than for prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Goods & Services

Pharmaceutical preparations, Namely for treating the digestive tract.

Goods & Services

Pharmaceutical preparations, Other than prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Goods & Services

Pharmaceutical preparations, other than prophylaxis for transplant rejections, uveitis, psoriasis, nephrotic syndrome, rheumatoid arthritis and dermatitis.

Goods & Services

Pharmaceutical preparations.